Serological autoantibody profiling of type 1 diabetes by protein arrays

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 486-496

  Miersch, Shane ^a   Bian, Xiaofang ^b   Wallstrom, Garrick ^b   Sibani, Sahar ^c   Logvinenko, Tanya ^d   Wasserfall, Clive H ^e   Schatz, Desmond ^e   Atkinson, Mark ^e   Qiu, Ji ^b   LaBaer, Joshua ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MILLIPORE CORPORATION   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Autoantibody; NAPPA; Protein array; Type 1 diabetes

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; AUTOANTIBODY; BIOLOGICAL MARKER; CALPAIN 11; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2; FOXM1 PROTEIN; G PROTEIN COUPLED RECEPTOR 120; HOXB7 PROTEIN; INTERLEUKIN 12 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY;

AAB; AUTOANTIBODY; COEFFICIENT OF VARIANCE; CV; FALSE DISCOVERY RATE; FDR; NAPPA; NUCLEIC ACID PROGRAMMABLE PROTEIN ARRAY; PROTEIN ARRAY; RECEIVER OPERATOR CHARACTERISTIC.; ROC; T1D; TSA; TYPE 1 DIABETES; TYRAMIDE SIGNAL AMPLIFICATION;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; PROTEIN ARRAY ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 84887524283     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.018     Document Type: Article

References (59)

1. Atkinson M.A., Maclaren N.K., Scharp D.W., Lacy P.E., Riley W.J. 64,000Mr autoantibodies as predictors of insulin-dependent diabetes. Lancet 1990, 335:1357-1360.
2. Palmer J.P., Asplin C.M., Clemons P., Lyen K., Tatpati O., Raghu P.K., et al. Insulin-antibodies in insulin-dependent diabetics before insulin-treatment. Science 1983, 222:1337-1339.
3. Bottazzo G.F., Florin-Christensen A., Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974, 2:1279-1283.
4. Wenzlau J.M., Juhl K., Yu L.P., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.
5. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., et al. Identification of the 64k autoantigen in insulin-dependent diabetes as the gaba-synthesizing enzyme glutamic-acid decarboxylase. Nature 1990, 347:151-156.
6. Bonifacio E., Lampasona V., Genovese S., Ferrari M., Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995, 155:5419-5426.
7. Wasserfall C.H., Atkinson M.A. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 2006, 5:424-428.
8. Christie M.R., Molvig J., Hawkes C.J., Carstensen B., Mandrup-Poulsen T., Contr C.-E.R. IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin. Diabetes Care 2002, 25:1192-1197.
9. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
10. Pozzilli P. The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes Metab Res Rev 2002, 18:257-259.
11. Achenbach P., Hummel M., Thumer L., Boerschmann H., Hofelmann D., Ziegler A.G. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetologia 2013, 56:1615-1622.
12. Bonifacio E., Ziegler A.G. Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am 2010, 39:513-525.
13. Raju R., Foote J., Banga J.P., Hall T.R., Padoa C.J., Dalakas M.C., et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 2005, 175:7755-7762.
14. Wang J., Miao D.M., Babu S., Yu J.S., Barker J., Klingensmith G., et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007, 92:88-92.
15. Song Q., Liu G., Hu S., Zhang Y., Tao Y., Han Y., et al. Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res 2010, 9:30-39.
16. Hueber W., Kidd B.A., Tomooka B.H., Lee B.J., Bruce B., Fries J.F., et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005, 52:2645-2655.
17. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008, 105:18889-18894.
18. Anderson K.S., Sibani S., Wallstrom G., Qiu J., Mendoza E.A., Raphael J., et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011, 10:85-96.
19. Madoz-Gurpide J., Kuick R., Wang H., Misek D.E., Hanash S.M. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 2008, 7:268-281.
20. Babel I., Barderas R., Diaz-Uriarte R., Martinez-Torrecuadrada J.L., Sanchez-Carbayo M., Casal J.I. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009, 8:2382-2395.
21. Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R., et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003, 3:2108-2115.
22. LaBaer J., Ramachandran N. Protein microarrays as tools for functional proteomics. Curr Opin Chem Biol 2005, 9:14-19.
23. Gibson D.S., Qiu J., Mendoza E.A., Barker K., Rooney M.E., LaBaer J. Circulating and synovial antibody profiling of juvenile arthritis patients by nucleic acid programmable protein arrays. Arthritis Res Ther 2012, 14:R77.
24. Burbelo P.D., Goldman R., Mattson T.L. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 2005, 5:22.
25. Miersch S., LaBaer J. Nucleic acid programmable protein arrays: versatile tools for array-based functional protein studies. Curr Protoc Protein Sci 2011, 2. [Chapter 27:Unit27].
26. Qiu J., LaBaer J. Nucleic acid programmable protein array a just-in-time multiplexed protein expression and purification platform. Methods Enzymol 2011, 500:151-163.
27. Sibani S., LaBaer J. Immunoprofiling using NAPPA protein microarrays. Methods Mol Biol 2011, 723:149-161.
28. Clutter M.R., Heffner G.C., Krutzik P.O., Sachen K.L., Nolan G.P. Tyramide signal amplification for analysis of kinase activity by intracellular flow cytometry. Cytometry A 2010, 77:1020-1031.
29. Koenker RaH K.F. Quantile regression. J Econ 2001, 15:143-156.
30. Rai A.J., Zhang Z., Rosenzweig J., Shih Ie M., Pham T., Fung E.T., et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002, 126:1518-1526.
31. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
32. David W., Lemeshow Stanley, Rodney X., Sturdivant Applied logistic regression 2013, 3rd ed.
33. Burbelo P.D., Hirai H., Leahy H., Lernmark A., Ivarsson S.A., Iadarola M.J., et al. A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2. Diabetes Care 2008, 31:1824-1826.
34. Ramachandran N., Raphael J.V., Hainsworth E., Demirkan G., Fuentes M.G., Rolfs A., et al. Next-generation high-density self-assembling functional protein arrays. Nat Methods 2008, 5:535-538.
35. Miele C., Raciti G.A., Cassese A., Romano C., Giacco F., Oriente F., et al. PED/PEA-15 regulates glucose-induced insulin secretion by restraining potassium channel expression in pancreatic beta-cells. Diabetes 2007, 56:622-633.
36. Kuliawat R., Kalinina E., Bock J., Fricker L., McGraw T.E., Kim S.R., et al. Syntaxin-6 SNARE involvement in secretory and endocytic pathways of cultured pancreatic beta-cells. Mol Biol Cell 2004, 15:1690-1701.
37. Burbelo P.D., Ching K.H., Klimavicz C.M., Iadarola M.J. Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J Vis Exp 32,2009, 1549-1551.
38. Scully T. Diabetes in numbers. Nature 2012, 485:S2-S3.
39. Wenzlau J.M., Moua O., Sarkar S.A., Yu L., Rewers M., Eisenbarth G.S., et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008, 1150:256-259.
40. Hameed S., Ellard S., Woodhead H.J., Neville K.A., Walker J.L., Craig M.E., et al. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Pediatr Diabetes 2011, 12:142-149.
41. Castano L., Russo E., Zhou L., Lipes M.A., Eisenbarth G.S. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab 1991, 73:1197-1201.
42. Pietropaolo M., Castano L., Babu S., Buelow R., Kuo Y.L., Martin S., et al. Islet cell autoantigen 69kD (ICA69). Molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest 1993, 92:359-371.
43. Dotta F., Falorni A., Tiberti C., Dionisi S., Anastasi E., Torresi P., et al. Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmun 1997, 10:585-588.
44. Pehuet-Figoni M., Alvarez F., Bach J.F., Chatenoud L. Autoantibodies in recent onset type-1 diabetic patients to a Mr 60K microsomal hepatic protein: new evidence for autoantibodies to the type-2 glucose transporter. Clin Exp Immunol 2000, 122:164-169.
45. Kasimiotis H., Fida S., Rowley M.J., Mackay I.R., Zimmet P.Z., Gleason S., et al. Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. Autoimmunity 2001, 33:95-101.
46. Abulafia-Lapid R., Gillis D., Yosef O., Atlan H., Cohen I.R. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun 2003, 20:313-321.
47. Chang Y.H., Shiau M.Y., Tsai S.T., Lan M.S. Autoantibodies against IA-2, GAD, and topoisomerase II in type 1 diabetic patients. Biochem Biophys Res Commun 2004, 320:802-809.
48. Hirai H., Miura J., Hu Y., Larsson H., Larsson K., Lernmark A., et al. Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens. Clin Immunol 2008, 127:366-374.
49. Baekkeskov S., Kanaani J., Jaume J.C., Kash S. Does GAD have a unique role in triggering IDDM?. J Autoimmun 2000, 15:279-286.
50. Ceroni A., Sibani S., Baiker A., Pothineni V.R., Bailer S.M., LaBaer J., et al. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. Mol Biosyst 2010, 6:1604-1610.
51. Marzo N., Ortega S., Stratmann T., Garcia A., Rios M., Gimenez A., et al. Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model. J Immunol 2008, 180:1189-1198.
52. Fiaschi-Taesch N., Bigatel T.A., Sicari B., Takane K.K., Salim F., Velazquez-Garcia S., et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes 2009, 58:882-893.
53. Skurat A.V., Dietrich A.D. Phosphorylation of Ser(640) in muscle glycogen synthase by DYRK family protein kinases. J Biol Chem 2004, 279:2490-2498.
54. Yoshida K. Role for DYRK family kinases on regulation of apoptosis. Biochem Pharmacol 2008, 76:1389-1394.
55. Hayes M.G., Pluzhnikov A., Miyake K., Sun Y., Ng M.C.Y., Roe C.A., et al. Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 2007, 56:3033-3044.
56. Schlosser M., Mueller P.W., Torn C., Bonifacio E., Bingley P.J. Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 2010, 53:2611-2620.
57. Yu L., Miao D., Scrimgeour L., Johnson K., Rewers M., Eisenbarth G.S. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012, 61:179-186.
58. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
59. Wong J., Sibani S., Lokko N.N., LaBaer J., Anderson K.S. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods 2009, 350:171-182.